Loading clinical trials...
Loading clinical trials...
A Phase II, Prospective, Double-blinded, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS CoV 2 Vaccine Candidate MVC COV1901 in Adolescents
Conditions
Interventions
MVC-COV1901(S protein with adjuvant)
MVC-COV1901(Saline)
Locations
5
Taiwan
Mackay Memorial Hospital Hsinchu
Hsinchu, Taiwan
Chang-Guang Memorial Hospital Lin-Kou
Taipei, Taiwan
MacKay Memorial Hospital
Taipei, Taiwan
National Taiwan University Hospital-HsinChu
Taipei, Taiwan
National Taiwan University Hosptial
Taipei, Taiwan
Start Date
July 22, 2021
Primary Completion Date
October 25, 2021
Completion Date
March 21, 2022
Last Updated
April 20, 2022
NCT04834869
NCT05175742
Lead Sponsor
Medigen Vaccine Biologics Corp.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions